Inovio Announces Clinical Trial Collaboration To Evaluate A Novel T-cell Immunotherapy In Combination With A PD-L1 … – Clinical Leader
|
Inovio Announces Clinical Trial Collaboration To Evaluate A Novel T-cell Immunotherapy In Combination With A PD-L1 …
Clinical Leader The phase 1b/2 immuno-oncology trial will evaluate Genentech's atezolizumab (TECENTRIQ®) in combination with Inovio's INO-5401, a T cell activating immunotherapy encoding multiple antigens, and INO-9012, an immune activator encoding IL-12. |
